GILD

GILD

USD

Gilead Sciences Inc. Common Stock

$118.840-5.050 (-4.076%)

Preço em tempo real

Healthcare
Drug Manufacturers - General
Estados Unidos

Gráfico de preços

Loading Chart...

Métricas-chave

Métricas de mercado
Fundamentos da empresa
Estatísticas de negociação

Métricas de mercado

Abertura

$123.890

Máximo

$124.000

Mínimo

$117.540

Volume

6.29M

Fundamentos da empresa

Capitalização de mercado

147.6B

Setor

Drug Manufacturers - General

País

United States

Estatísticas de negociação

Volume médio

6.96M

Bolsa de valores

NMS

Moeda

USD

Faixa de 52 semanas

Mínimo $86.08Atual $118.840Máximo $124.61

Notícias relacionadas

BusinessWire

Gilead Sciences to Present at Upcoming Investor Conferences

Gilead Sciences, Inc. (NASDAQ:GILD) announced today that its executives will be speaking at the following investor conferences: UBS Global Healthcare Conference on Monday, November 10 at 11:00 AM Eastern

Ver mais
Gilead Sciences to Present at Upcoming Investor Conferences
Analyst Upgrades

Truist Securities Reiterates Buy on Gilead Sciences, Raises Price Target to $145

Truist Securities analyst Asthika Goonewardene reiterates Gilead Sciences with a Buy and raises the price target from $127 to $145.

Ver mais
Truist Securities Reiterates Buy on Gilead Sciences, Raises Price Target to $145
BusinessWire

Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025

– Updated Results from Phase 2 Pivotal iMMagine-1 Study of Anito-cel for Relapsed/Refractory Multiple Myeloma to be Presented Orally – – New Findings Reinforce Yescarta's® Curative Potential as Second-Line

Ver mais
Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025
Analyst Upgrades

JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $150

JP Morgan analyst Chris Schott maintains Gilead Sciences with a Overweight and raises the price target from $145 to $150.

Ver mais
JP Morgan Maintains Overweight on Gilead Sciences, Raises Price Target to $150
Analyst Upgrades

Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026

Gilead beats estimates, raises 2025 guidance, driven by strong HIV and liver drug sales and multiple launches planned for 2026.

Ver mais
Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026
Analyst Upgrades

RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $105

RBC Capital analyst Brian Abrahams maintains Gilead Sciences with a Sector Perform and raises the price target from $100 to $105.

Analyst Upgrades

Cantor Fitzgerald Reiterates Overweight on Gilead Sciences, Maintains $135 Price Target

Cantor Fitzgerald analyst Carter Gould reiterates Gilead Sciences with a Overweight and maintains $135 price target.

Mantenha-se atualizado

Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.